Literature DB >> 3175972

Changes in bronchial responsiveness to inhaled histamine over four years in middle aged male smokers and ex-smokers.

T K Lim1, R G Taylor, A Watson, H Joyce, N B Pride.   

Abstract

Bronchial hyperresponsiveness to inhaled histamine in smokers is associated with an accelerated annual decline in FEV1 and low baseline FEV1 values. The evolution of bronchial hyperresponsiveness and whether it precedes or follows the accelerated decline in FEV1 and reduction in FEV1 is unknown. Measurements of the provocative concentration of inhaled histamine required to reduce FEV1 by 20% (PC20) were repeated after a four year interval in 27 male smokers (mean age 59 years, smoking on average 27 cigarettes a day in 1986) and 16 men who were ex-smokers in 1982 and who remained non-smokers until 1986 (mean age 53 years in 1986). These men were originally recruited to a prospective study in 1974 and had their first PC20 measurement in 1982. PC20 was positively related to baseline FEV1 in both smokers and ex-smokers in both 1982 and 1986 (r ranging from 0.56 to 0.76, p less than 0.01). In smokers mean FEV1 fell from 83% to 77% predicted (p less than 0.001) and geometric mean PC20 from 7.11 to 3.27 mg/ml (p less than 0.001) between 1982 and 1986. The change in PC20 in individual smokers over the four years was related to change in FEV1 (p = 0.012). In ex-smokers mean FEV1 was 93% predicted both in 1982 and in 1986 and there was no significant difference in geometric mean PC20 between 1982 (6.68 mg/ml) and 1986 (5.98 mg/ml). Thus in smokers there was an accelerated annual decline in FEV1 and an increase in bronchial hyperresponsiveness as FEV1 fell. The ex-smokers had comparable levels of bronchial hyperresponsiveness in 1982. Mean PC20 values were unchanged in 1986 in these men, who showed a normal age related decline in FEV1. These longitudinal results emphasise the importance of baseline airway geometry in influencing bronchial hyperresponsiveness to histamine in middle aged smokers and ex-smokers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3175972      PMCID: PMC461394          DOI: 10.1136/thx.43.8.599

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  18 in total

1.  The natural history of chronic airflow obstruction.

Authors:  C Fletcher; R Peto
Journal:  Br Med J       Date:  1977-06-25

2.  Bronchial reactivity to inhaled histamine: a method and clinical survey.

Authors:  D W Cockcroft; D N Killian; J J Mellon; F E Hargreave
Journal:  Clin Allergy       Date:  1977-05

3.  Nonspecificity of the bronchoconstricting effect of histamine and acetyl-beta-methylcholine in patients with obstructive airway disease.

Authors:  R C Klein; J E Salvaggio
Journal:  J Allergy       Date:  1966-03

Review 4.  Bronchial hyperresponsiveness as a risk factor for progressive airflow obstruction in smokers.

Authors:  N B Pride; R G Taylor; T K Lim; H Joyce; A Watson
Journal:  Bull Eur Physiopathol Respir       Date:  1987 Jul-Aug

Review 5.  Physiological aspects of primary hypertension.

Authors:  B Folkow
Journal:  Physiol Rev       Date:  1982-04       Impact factor: 37.312

6.  The use of tests of peripheral lung function for predicting future disability from airflow obstruction in middle-aged smokers.

Authors:  S F Tattersall; M K Benson; D Hunter; A Mansell; N B Pride; C M Fletcher
Journal:  Am Rev Respir Dis       Date:  1978-12

7.  Elastolytic activity of alveolar macrophages in chronic bronchitis: comparison of current and former smokers.

Authors:  S O'Neill; J S Prichard
Journal:  Thorax       Date:  1983-05       Impact factor: 9.139

8.  Relationship of constitutional factors and cigarette smoking to decrease in 1-second forced expiratory volume.

Authors:  C E Barter; A H Campbell
Journal:  Am Rev Respir Dis       Date:  1976-03

9.  Bronchial hyperreactivity in chronic obstructive bronchitis.

Authors:  J W Ramsdell; F J Nachtwey; K M Moser
Journal:  Am Rev Respir Dis       Date:  1982-11

10.  Bronchial reactivity to methacholine in ten non-obstructive heavy smokers before and up to one year after cessation of smoking.

Authors:  B G Simonsson; C Rolf
Journal:  Eur J Respir Dis       Date:  1982-11
View more
  6 in total

Review 1.  Inhaled steroids for COPD?

Authors:  A E Tattersfield; T W Harrison
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease.

Authors:  B Auffarth; D S Postma; J G de Monchy; T W van der Mark; M Boorsma; G H Koëter
Journal:  Thorax       Date:  1991-05       Impact factor: 9.139

3.  Asthma, airways responsiveness and air pollution in two contrasting districts of northern England.

Authors:  G Devereux; T Ayatollahi; R Ward; C Bromly; S J Bourke; S C Stenton; D J Hendrick
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

Review 4.  Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2003-02       Impact factor: 8.667

5.  Factors affecting peak expiratory flow variability and bronchial reactivity in a random population sample.

Authors:  B G Higgins; J R Britton; S Chinn; K K Lai; P G Burney; A E Tattersfield
Journal:  Thorax       Date:  1993-09       Impact factor: 9.139

Review 6.  Systematic review of the evidence relating FEV1 decline to giving up smoking.

Authors:  Peter N Lee; John S Fry
Journal:  BMC Med       Date:  2010-12-14       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.